Poised for Innovation: Considerations for End Points for New Drug Development in Kidney Transplantation.
作者信息
Mannon Roslyn B, Vincenti Flavio G
机构信息
Division of Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Department of Medicine and Surgery, University of California at San Francisco, San Francisco, California.
出版信息
J Am Soc Nephrol. 2024 Nov 1;35(11):1603-1606. doi: 10.1681/ASN.0000000000000475. Epub 2024 Aug 5.
Abstract
摘要
相似文献
1
Poised for Innovation: Considerations for End Points for New Drug Development in Kidney Transplantation.为创新做好准备：肾移植新药研发终点的考量
J Am Soc Nephrol. 2024 Nov 1;35(11):1603-1606. doi: 10.1681/ASN.0000000000000475. Epub 2024 Aug 5.
2
End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.肠性高草酸尿症临床试验的终点考虑因素。
Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1637-1644. doi: 10.2215/CJN.0000000000000234. Epub 2023 Jun 21.
3
Effect of pre-end-stage kidney disease nephrology care on the association between neighborhood poverty and referral for kidney transplantation among patients with end-stage kidney disease.终末期肾病前期肾病护理对社区贫困与终末期肾病患者肾移植转诊之间关联的影响。
J Clin Epidemiol. 2025 Jun 24;185:111878. doi: 10.1016/j.jclinepi.2025.111878.
4
Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation.常温及低温机器灌注保存与静态冷藏在尸体供肾移植中的比较。
Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD011671. doi: 10.1002/14651858.CD011671.pub3.
5
Organ storage in renal transplantation.器官在肾移植中的储存。
Curr Opin Urol. 2024 Jan 1;34(1):8-13. doi: 10.1097/MOU.0000000000001139. Epub 2023 Nov 2.
6
Association of Public Reporting of Medicare Dialysis Facility Quality Ratings With Access to Kidney Transplantation.医疗保险透析机构质量评级公开报告与获得肾脏移植机会的关联。
JAMA Netw Open. 2021 Sep 1;4(9):e2126719. doi: 10.1001/jamanetworkopen.2021.26719.
7
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.用于治疗肾移植受者中已存在的和新发糖尿病的降糖药物。
Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD009966. doi: 10.1002/14651858.CD009966.pub2.
8
Bariatric surgery improves access to renal transplantation and is safe in renal failure as well as after transplantation: A systematic review and meta-analysis.减重手术可改善接受肾移植的机会，并且在肾衰竭和移植后也是安全的：系统评价和荟萃分析。
Transplant Rev (Orlando). 2023 Jul;37(3):100777. doi: 10.1016/j.trre.2023.100777. Epub 2023 Jul 8.
9
Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.在日本基于终末期肝病模型评分的分配政策下，成人慢性终末期肝病候选者接受已故供体肝移植的等待名单死亡率及移植概率的现状。
J Gastroenterol. 2025 Aug 14. doi: 10.1007/s00535-025-02288-y.
10
Toward Natural Products-Based Drug Development for Erectile Dysfunction: A Molecular Candidate from Plant Identified by an Integrated Study.走向基于天然产物的勃起功能障碍药物开发：通过综合研究鉴定出的一种植物分子候选物。
OMICS. 2025 Sep;29(9):442-457. doi: 10.1177/15578100251370567. Epub 2025 Aug 22.
引用本文的文献
1
New Immunosuppressants in Pediatric Kidney Transplantation: What's in the Pipeline for Kids?儿科肾移植中的新型免疫抑制剂：儿童领域有哪些正在研发的药物？
Pediatr Transplant. 2025 Feb;29(1):e70008. doi: 10.1111/petr.70008.
本文引用的文献
1
A brief review of the current status of pig islet xenotransplantation.猪胰岛异种移植现状简述。
Front Immunol. 2024 Feb 23;15:1366530. doi: 10.3389/fimmu.2024.1366530. eCollection 2024.
2
Longitudinal estimated glomerular filtration rate (eGFR) modeling in long-term renal function to inform clinical trial design in kidney transplantation.长期估算肾小球滤过率（eGFR）模型在长期肾功能中的应用，为肾脏移植临床试验设计提供信息。
Clin Transl Sci. 2023 Sep;16(9):1680-1690. doi: 10.1111/cts.13579. Epub 2023 Jul 10.
3
Acute Rejection After Kidney Transplant-An Endpoint Not Predictive of Treatment Effect on Graft Survival.肾移植后的急性排斥反应——一个不能预测对移植物存活治疗效果的终点指标
Transplantation. 2024 Mar 1;108(3):593-597. doi: 10.1097/TP.0000000000004696. Epub 2023 Jun 16.
4
The Role of Patient-reported Outcomes and Medication Adherence Assessment in Patient-focused Drug Development for Solid Organ Transplantation.患者报告结局和药物依从性评估在实体器官移植以患者为中心的药物研发中的作用
Transplantation. 2021 May 1;105(5):941-944. doi: 10.1097/TP.0000000000003556.
5
Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report.利用生物标志物改善肾器官移植中免疫抑制药物的研发及治疗效果：会议报告
Am J Transplant. 2020 Jun;20(6):1495-1502. doi: 10.1111/ajt.15833. Epub 2020 Mar 17.
6
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.移植肾受者移植肾丢失风险预测系统：国际推导和验证研究。
BMJ. 2019 Sep 17;366:l4923. doi: 10.1136/bmj.l4923.
7
Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report.移植中的致敏：风险评估（STAR）2017 工作组会议报告。
Am J Transplant. 2018 Jul;18(7):1604-1614. doi: 10.1111/ajt.14752. Epub 2018 May 22.
8
Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction.移植免疫抑制的临床试验：改革和改变方向的案例。
Transplantation. 2017 Jul;101(7):1527-1534. doi: 10.1097/TP.0000000000001648.
9
Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants.肾移植后估算肾小球滤过率下降与不良结局之间的关系。
J Am Soc Nephrol. 2016 Nov;27(11):3440-3446. doi: 10.1681/ASN.2015050524. Epub 2016 Apr 8.
10
Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward.为下一代移植受者开发新型免疫抑制疗法：前进之路。
Am J Transplant. 2016 Apr;16(4):1094-101. doi: 10.1111/ajt.13582. Epub 2016 Jan 5.
Zotero 插件